Researchers at Cincinnati Children’s Hospital have developed and tested a rapid blood assay that measures five biomarkers and precisely predicts those patients who stand at low, medium or high risk for death from sepsis.

The test, Persevere, enables doctors to identify and classify sepsis when the body is due to release the bacterial infection.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Upon understanding the five proteins / genes that make up the assay’s five-biomarker blood panel, doctors can commence immediate medical interventions.

Cincinnati Children’s Hospital critical care medicine director Hector Wong said that besides stratifying the patients into low, medium and high-risk groups, the biomarker test enables doctors to choose the right interventions for particular patients, including the drugs and dosages.

Wong, the study’s investigator, added: “The Persevere platform focuses on stratification and prognostication, not diagnostics. Prognostic enrichment is a fundamental tool of precision medicine. It allows us to predict the disease course and progression in individuals and tailor treatment to different groups of patients and individuals.”

The assay platform enables researchers to gain vital clues to analyse the underlying biological mechanisms of how sepsis commences, as well as how it is released into the body and how it can be prevented therapeutically.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sepsis especially impacts fragile young children and the elderly hospitalised in intensive care units, killing over 200,000 individuals annually.

For over a decade, the tool has been in development by the researchers, who reduced the number of biomarkers in the assay platform from 80 down to five, making it easier to blend technologies such as computer-assisted biology and informatics with laboratory experimentation for therapies.